Sequential drain amylase to guide drain removal following pancreatectomy

HPB (Oxford). 2018 Jun;20(6):514-520. doi: 10.1016/j.hpb.2017.11.008. Epub 2018 Feb 23.

Abstract

Background: Although used as criterion for early drain removal, postoperative day (POD) 1 drain fluid amylase (DFA) ≤ 5000 U/L has low negative predictive value for clinically relevant postoperative pancreatic fistula (CR-POPF). It was hypothesized that POD3 DFA ≤ 350 could provide further information to guide early drain removal.

Methods: Data from a pancreas surgery consortium database for pancreatoduodenectomy and distal pancreatectomy patients were analyzed retrospectively. Those patients without drains or POD 1 and 3 DFA data were excluded. Patients with POD1 DFA ≤ 5000 were divided into groups based on POD3 DFA: Group A (≤350) and Group B (>350). Operative characteristics and 60-day outcomes were compared using chi-square test.

Results: Among 687 patients in the database, all data were available for 380. Fifty-five (14.5%) had a POD1 DFA > 5000. Among 325 with POD1 DFA ≤ 5000, 254 (78.2%) were in Group A and 71 (21.8%) in Group B. Complications (35 (49.3%) vs 87 (34.4%); p = 0.021) and CR-POPF (13 (18.3%) vs 10 (3.9%); p < 0.001) were more frequent in Group B.

Conclusions: In patients with POD1 DFA ≤ 5000, POD3 DFA ≤ 350 may be a practical test to guide safe early drain removal. Further prospective testing may be useful.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Amylases / metabolism*
  • Biomarkers / metabolism
  • Clinical Enzyme Tests*
  • Databases, Factual
  • Device Removal / adverse effects
  • Device Removal / methods*
  • Drainage / adverse effects
  • Drainage / instrumentation*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatectomy* / adverse effects
  • Pancreatic Fistula / etiology
  • Pancreatic Fistula / prevention & control
  • Pancreaticoduodenectomy* / adverse effects
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Time-to-Treatment*
  • Treatment Outcome

Substances

  • Biomarkers
  • Amylases